Presentation is loading. Please wait.

Presentation is loading. Please wait.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Published byMetin Şen Modified over 4 years ago

Similar presentations

Presentation on theme: "Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)"— Presentation transcript:

1 Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Data are shown as percentage of CD11b+CD14+ cells and median (*p<0.05). Daniel Aeberli et al. RMD Open 2016;2:e000079 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)"

Similar presentations

Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.

Monthly improvements in paid work productivity: ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) subpopulations (employed.
Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.

Monthly improvements in family, social and leisure activities to week 96 (last observation carried forward imputation). Assessed using the arthritis-specific.
Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.
Summary of TB cases across indications and trial periods

Summary of TB cases across indications and trial periods
The genomic region spanning rs shows enhancer activity.

The genomic region spanning rs shows enhancer activity.
Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.

Patients included in linear extrapolation and observed/last observation carried forward analyses at week 48. Patients who were rescued or discontinued.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.
Main fields of interest.

Main fields of interest.
Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.

Conversion to ACPA and RF seronegative status in patients with early RA treated with abatacept+MTX compared with MTX alone. Conversion to ACPA and RF seronegative.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.
Patient disposition through 48 weeks in RA-BEYOND

Patient disposition through 48 weeks in RA-BEYOND
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.
The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.
Pathogenesisof PsA and RA

Pathogenesisof PsA and RA

Similar presentations

Ads by Google